Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Evaluation And Management Of Myasthenia Gravis

J. Keesey
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Myasthenia gravis (MG) is a syndrome of fluctuating skeletal muscle weakness that worsens with use and improves with rest. Eye, facial, oropharyngeal, axial, and limb muscles may be involved in varying combinations and degrees of severity. Its etiology is heterogeneous, divided initially between those rare congenital myasthenic syndromes, which are genetic, and the bulk of MG, which is acquired and autoimmune. The autoimmune conditions are divided in turn between those that possess measurable serum acetylcholine receptor (AChR) antibodies and a smaller group that does not. The latter group includes those MG patients who have serum antibodies to muscle‐specific tyrosine kinase (MuSK). Therapeutic considerations differ for early‐onset MG, late‐onset MG, and MG associated with the presence of a thymoma. Most MG patients can be treated effectively, but there is still a need for more specific immunological approaches. Muscle Nerve 29: 484–505, 2004
This paper references
10.1212/WNL.52.3.629
Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis
A. Qureshi (1999)
10.1002/(SICI)1097-4598(199909)22:9<1297::AID-MUS22>3.0.CO;2-C
Myasthenia gravis in the tenth decade
L. H. Phillips (1999)
10.1016/S0010-7824(03)00136-7
Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety.
C. Westhoff (2003)
10.1212/WNL.16.5.431
Myasthenia gravis
V. Perlo (1966)
10.1111/j.1749-6632.1981.tb33765.x
ASPECTS OF THE NATURAL HISTORY OF MYASTHENIA GRAVIS: CRISIS AND DEATH
M. Cohen (1981)
10.1111/J.1749-6632.1981.TB33771.X
PLASMA EXCHANGE ALONE AS THERAPY FOR MY ASTHENIA GRAVIS *
J. Keesey (1981)
10.1016/0022-510X(91)90260-E
Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients
E. Beghi (1991)
10.1212/WNL.36.11.1533
Monitoring azathioprine therapy in myasthenia gravis
A. Witte (1986)
Malignant thymoma with renal metastases: report of a case
SA Hietala (1978)
10.1016/S0003-4975(10)66861-0
Thymectomy for myasthenia gravis: recent observations and comparisons with past experience.
D. Mulder (1989)
Thymectomy for myasthenia gravis: analysis of the controversy regarding technique and results. Neurology 1997;48(Suppl 5):S52–S63
A. Jaretzki (1997)
Seronegative generalized myasthenia gravis: low frequency of thymic pathology
PK Verma (1992)
10.1016/0002-8703(71)90114-1
Cardiac arrest during edrophonium administration.
L. Gould (1971)
[Seronegative myasthenia gravis].
P. Gajdos (2004)
10.2214/AJR.148.3.515
Mediastinal imaging in myasthenia gravis: correlation of chest radiography, CT, MR, and surgical findings.
P. Batra (1987)
10.1016/0013-4694(85)90102-6
Congenital myasthenic syndromes.
A. Engel (1998)
10.1002/ANA.410240619
Myasthenia gravis: Discontinuation of long‐term azathioprine
M. Michels (1988)
10.1016/S0022-510X(03)00087-X
Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up
R. Mantegazza (2003)
Atlas of tumor pathology, 2nd series. Fascicle 13, Tumors of the thymus
J Rosai (1976)
10.1001/ARCHNEUR.1986.00520020083029
Successful plasmapheresis for fulminant myasthenia gravis during pregnancy.
S. E. Levine (1986)
10.1016/S0140-6736(74)92431-3
Letter: Acute anterior uveitis and HL-A 27.
D. Brewerton (1974)
10.1016/S0025-6196(12)65645-6
Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow.
N. Čikeš (1988)
Myasthenia gravis: evaluation of treatment in 1335 patients
VP Perlo (1966)
10.1038/sj.bmt.1701297
Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation
F. Baron (1998)
10.1001/JAMA.1930.27120410003009C
A REPORT OF PROGRESS ON THE USE OF EPHEDRINE IN A CASE OF MYASTHENIA GRAVIS
H. Edgeworth (1930)
10.1146/ANNUREV.PA.17.040177.002455
Clinical pharmacology of systemic corticosteroids.
J. Melby (1977)
10.1111/j.1749-6632.1998.tb11014.x
A Treatment Algorithm for Autoimmune Myasthenia in Adults
J. Keesey (1998)
10.1001/ARCHNEUR.1991.00530190081019
Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.
F. Somnier (1991)
10.1002/cpt1973143380
Theophylline compounds and myasthenia gravis; II. Clinical report of nine cases
J. Brumlik (1973)
10.1056/NEJM197701202960301
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
K. Toyka (1977)
10.1111/j.1600-0404.1991.tb04899.x
Effectiveness of steroid treatment in myasthenia gravis: a retrospective study
V. Cosi (1991)
Functional imaging of thymic disorders.
S. Lastoria (1999)
10.1111/J.1749-6632.1987.TB51318.X
Clinical Experience in More Than 2000 Patients with Myasthenia Gravis
G. Genkins (1987)
10.1007/BF00315656
A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy
R. Mantegazza (2004)
10.1212/WNL.58.1.150-a
Presentation of myasthenia gravis mimicking blepharospasm
M. Roberts (2002)
10.1007/s100720200011
High-dose intravenous immunoglobulin G treatment of myasthenia gravis
B. Ferrero (2002)
10.1093/BRAIN/AWG223
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
A. Evoli (2003)
10.1212/WNL.39.2.308-a
Etiology of syringomyelia
J. M. Milstein (1989)
10.1159/000116785
Long-term results of corticosteroid therapy in patients with myasthenia gravis.
A. Evoli (1992)
[Drugs and myasthenia gravis].
J. Petrášek (1984)
10.1136/jnnp.47.5.555
Strong association of HLA BW46 with juvenile onset myasthenia gravis in Hong Kong Chinese.
B. Hawkins (1984)
10.1212/WNL.48.5.1253
Myasthenic crisis
C. E. Thomas (1997)
10.1136/jnnp.56.4.382
Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese.
W. Chen (1993)
10.1212/WNL.30.9.939
Dysthyroid and myasthenic myopathy of the medial rectus
T. Spoor (1980)
10.1159/000050800
Prognostic Factors of Thymectomy in Patients with Myasthenia gravis: A Cohort of 132 Patients
J. Téllez-Zenteno (2001)
10.1002/ANA.410290209
HLA class II antigens and DNA restriction fragment length polymorphism in myasthenia gravis in japan
K. Morita (1991)
10.1136/jnnp.58.6.729
Familial autoimmune myasthenia gravis: report of four families.
A. Evoli (1995)
10.1212/WNL.39.6.865
A false‐positive edrophonium test in a patient with a brainstem glioma
L. Y. Dirr (1989)
Are studies of fatigue worth the effort? Neurology 2003;60:1057–1058
Schwind (2003)
10.1016/S1567-424X(09)70143-6
The clinical neurophysiology of diseases of neuromuscular transmission.
D. Sanders (2000)
10.1016/0022-510X(72)90075-5
Isotope studies of body composition in neuromuscular diseases.
P. Delwaide (1972)
10.1002/ANA.410410615
Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis
P. Gajdos (1997)
10.1212/WNL.55.3.448
Retrospective analysis of the use of cyclosporine in myasthenia gravis
E. Ciafaloni (2000)
10.1001/jama.289.6.758
Myasthenia Gravis: An Illustrated History
R. Ruff (2003)
10.1002/ANA.410110603
A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine‐induced ion channel
A. Engel (1982)
10.1001/ARCHNEUR.60.7.1024-A
Cognitive decline in Down syndrome.
M. L. Margallo-Lana (2003)
Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin.
R. Stricker (1993)
10.1212/WNL.50.6.1778
A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis
J. Palace (1998)
Myasthenia gravis, a higher than expected incidence in the elderly
JM Aragonès (2003)
10.1097/01.npr.0000419290.91466.6e
Myasthenia gravis. I
V. Carmena (1961)
10.1002/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N
Complications of intravenous gammaglobulin in neuromuscular and other diseases
T. Bertorini (1996)
10.1177/003693306000501001
Myasthenia Gravis: A New Hypothesis
J. Simpson (1960)
10.1212/WNL.48.Suppl_5.23S
Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome
V. Lennon (1997)
10.1212/01.WNL.0000065882.63904.53
Clinical aspects of MuSK antibody positive seronegative MG
D. Sanders (2003)
10.1097/01.LAB.0000028144.48023.9B
Anti-P110 Autoantibodies Identify a Subtype of “Seronegative” Myasthenia Gravis with Prominent Oculobulbar Involvement
F. Scuderi (2002)
10.1038/SCIENTIFICAMERICAN1162-50
The Thymus Gland
Sir Macfarlane Burnet (1962)
10.1002/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C
Effect of high‐dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases
B. M. Koffman (1997)
New York: Grune & Stratton
K E Osserman (1958)
Thymectomy for myasthenia gravis : analysis of the controversy regarding technique and results
A Jaretzki (1997)
Extended transsternal thymectomy.
Mulder Dg (1996)
10.1093/AJHP/54.3.285
Mycophenolate mofetil: a unique immunosuppressive agent.
K. Hood (1997)
10.1111/j.1749-6632.1998.tb11015.x
Reliability Testing of the Quantitative Myasthenia Gravis Score a
R. Barohn (1998)
10.1093/BRAIN/103.3.579
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.
D. Compston (1980)
Striated muscle antibody and computed tomography may miss inva502 Myasthenia Gravis MUSCLE & NERVE April 2004 sive thymoma in myasthenia gravis
JC Keesey (1986)
10.1111/j.1749-6632.1981.tb33767.x
EFFECT OF IMMUNOSUPPRESSIVE DRUGS (AZATHIOPRINE)
H. Mertens (1981)
10.1002/ANA.410060107
Pupillary dysfunction in myasthenia gravis
F. E. Lepore (1979)
10.1001/ARCHINTE.1997.00440250045006
Drugs and myasthenia gravis. An update.
E. Wittbrodt (1997)
10.1111/J.1939-1676.1990.TB03124.X
Acquired myasthenia gravis. Selective involvement of esophageal, pharyngeal, and facial muscles.
G. Shelton (1990)
10.1136/jnnp.48.4.332
Thymectomy in myasthenia with pure ocular symptoms.
F. Schumm (1985)
10.1212/WNL.29.1.29
Eye movement fatigue in myasthenia gravis
J. Spooner (1979)
10.1212/WNL.60.7.1057
April 8 Highlights
Lippincott Williams Wilkins (2003)
10.1126/science.182.4109.293
Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors
D. Fambrough (1973)
10.1076/jhin.12.2.167.15532
The Role of Herman Hoppe of Cincinnati in the Initial Clinical Recognition of Myasthenia Gravis
J. Keesey (2003)
10.1212/WNL.26.11.1054
Antibody to acetylcholine receptor in myasthenia gravis
J. Lindstrom (1976)
Myasthenia gravis: prolonged treatment with steroids
A Sghirlanzoni (1984)
The human thymus in disease with particular emphasis on thymitis and thymoma
K Henry
10.1212/WNL.41.6.923
Repeat thymectomy in chronic refractory myasthenia gravis
R. Miller (1991)
10.1001/ARCHNEUR.56.1.25
Late-onset myasthenia gravis: a changing scene.
J. Aarli (1999)
10.1111/J.1464-410X.1982.TB08946.X
Urinary incontinence following prostatectomy in patients with myasthenia gravis.
G. Wise (1982)
10.1016/S0140-6736(75)92203-5
Myasthenia Gravis
D. Elmqvist (1966)
10.1159/000070185
Thymectomy in Nonthymoma Early-Onset Myasthenia gravis in Correlation with Disease Severity and Muscle Autoantibodies
F. Romi (2003)
10.1212/WNL.44.3_Part_1.551
Familial autoimmune myasthenia gravis
J. Bergoffen (1994)
10.1093/OXFORDJOURNALS.QJMED.A068141
Treatment of myasthenia gravis: an audit.
J. Simpson (1987)
Myasthenia gravis without chronic GVHD after allogeneic bone marrow transportation. Bone Marrow Transplantation
F Baron (1998)
Are studies of fatigue worth the effort ?
Schwind (2003)
10.1056/NEJM198001033020103
Ambulatory medical care: a comparison of internists and family-general practitioners.
J. Noren (1980)
10.1002/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B
Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
M. Dalakas (1999)
Experimental Staphylococcus Infection in Man
W. Foster (1960)
10.1016/S0022-5347(17)59693-7
Transurethral prostatic resection in patients with myasthenia gravis.
L. Greene (1974)
10.1212/WNL.48.Suppl_5.52S
Thymectomy for myasthenia gravis
A. Jaretzki (1997)
10.1212/WNL.56.1.97
Mycophenolate mofetil for myasthenia gravis: An open-label pilot study
E. Ciafaloni (2001)
10.1056/NEJM198703193161205
Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.
R. Tindall (1987)
Facial weakness without ocular weakness in myasthenia gravis.
L. G. Chia (1988)
10.1016/S0140-6736(86)92259-2
MYASTHENIA GRAVIS WITHOUT ACETYLCHOLINE-RECEPTOR ANTIBODY: A DISTINCT DISEASE ENTITY
S. Mossman (1986)
10.1212/WNL.31.4.476
Myasthenia gravis in infancy
M. Seybold (1981)
Exacerbation of myasthenia during the menstrual period
RR Leker (1998)
10.1002/mus.10095
“Crisis” in myasthenia gravis: An historical perspective
J. Keesey (2002)
10.1016/S0003-4975(02)03722-0
Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy.
J. Shrager (2002)
10.1001/ARCHNEUR.58.6.885
Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients.
A. M. Yamamoto (2001)
10.3109/00016923809137767
Zur Rontgenologischen Differentialdiagnose Zwischen Pleuritis und Empyem Nebst Einigen Wichtigen Klinischen Daten
Sten Oldberg (1938)
Myasthenia gravis, an illustrated history. Roseville: Publishers Design Group
J C Keesey (2002)
Thymectomy in nonthymomatous early-onset myasthenia gravis in correlations with disease severity and muscle antibodies
F Romi (2003)
10.1136/jnnp.52.10.1121
The natural course of myasthenia gravis: a long term follow up study.
H. Oosterhuis (1989)
10.1212/WNL.37.12.1854
Myasthenia gravis
H. C. Chiu (1987)
10.1212/WNL.51.4.933-A
Antibody to acetylcholine receptor in myasthenia gravis
J. Lindstrom (1998)
10.1002/MUS.880120802
AAEE minimonograph #33: Electrodiagnostic approach to defects of neuromuscular transmission
J. C. Keesey (1989)
10.1001/ARCHNEUR.57.11.1596
The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
F. Romi (2000)
10.1212/WNL.47.5.1233
Epidemiologic evidence for a changing natural history of myasthenia gravis
L. H. Phillips (1996)
Seronegative myasthenia gravis. Neurology 1997;48(Suppl 5):S40–S45
DB Sanders (1997)
10.1111/j.1749-6632.1998.tb11010.x
Thymectomy in Childhood Myasthenia Gravis
M. Seybold (1998)
10.1136/jnnp.46.4.361
HLA antigens and myasthenia gravis in north India.
N. Mehra (1983)
10.1001/ARCHINTE.1984.00350160117020
Disorders of the thymus. A review.
E. Rosenow (1984)
10.1016/S0003-4975(00)01595-2
Myasthenia gravis: recommendations for clinical research standards1
A. Jaretzki (2000)
Ocular myasthenia gravis: a critical review of clinical and pathophysiological aspects
N Sommer (1993)
10.1016/S0165-2478(03)00133-0
Low T cell receptor excision circle levels in patients thymectomized 25-54 years ago.
J. Storek (2003)
10.1212/WNL.36.2.297
Target fibers in multiple sclerosis
J. Riggs (1986)
10.1111/j.1749-6632.1993.tb22937.x
A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravis a
R. Tindall (1993)
10.1007/S11910-002-0057-7
Congenital myasthenic syndromes: Genetic defects of the neuromuscular junction
K. Ohno (2002)
10.1002/MUS.880040314
Antibody-negative acquired myasthenia gravis: successful therapy with plasma exchange.
M. Rg (1981)
10.1016/S0140-6736(79)90823-7
LONG-TERM EFFECTS OF REPEATED PLASMA EXCHANGE IN MYASTHENIA GRAVIS
J. Newsom-Davis (1979)
10.1212/WNL.30.3.233
Detection of thymoma in myasthenia gravis
J. Keesey (1980)
The frequency of muscle involvement in myasthenia gravis correlates with mean muscle temperature.
C. Jablecki (1982)
Serologic profile of myasthenia gravis and distinction from the Lambert–Eaton syndrome. Neurology 1997;48(Suppl 5):S23–S27
VA Lennon (1997)
10.1016/S0140-6736(76)91917-6
REMISSION OF MYASTHENIA GRAVIS FOLLOWING PLASMA-EXCHANGE
A. Pinching (1976)
10.32388/zkhopa
Transient neonatal myasthenia gravis.
Ó. Papazian (1992)
10.1177/088307389200700202
Topical Review Article: Transient Neonatal Myasthenia Gravis
Ó. Papazian (1992)
Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets
A Vincent (2003)
10.1016/S0003-4975(96)00376-1
Extended thymectomy for myasthenia gravis patients: a 20-year review.
A. Masaoka (1996)
10.1001/ARCHNEUR.1985.04060110031011
High-dose intravenous methylprednisolone in myasthenia gravis.
E. Arsura (1985)
Antibody-negative acquired myasthenia gravis: successful therapy with plasma exchange.
R. Miller (1981)
Fascicle 13, Tumors of the thymus. Bethesda: Armed Forces Institute of Pathology
J Rosai (1976)
10.1002/MUS.880010304
Myasthenia gravis: Review of diagnosis and management
B. Patten (1978)
10.1212/WNL.55.1.7
Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review)
G. Gronseth (2000)
Mycophenolate mofetil for myasthenic gravis: an open-label study
E Ciafaloni (2001)
10.1212/WNL.40.11.1663
Why are eye muscles frequently involved in myasthenia gravis?
H. Kaminski (1990)
10.1016/S0003-4975(99)00167-8
Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis.
M. Tsuchida (1999)
10.1212/WNL.31.1.32
Stable remissions in myasthenia grams
M. C. Perez (1981)
10.1002/ANA.410150316
Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 Patients
R. Pascuzzi (1984)
10.1002/mus.10133
Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis
Lucas Gustavo De Feo (2002)
10.1016/0090-1229(89)90083-4
Experience with intravenous immunoglobulin in myasthenia gravis.
E. Arsura (1989)
10.1001/ARCHNEUR.1982.00510180028007
Complications of plasma exchange in neurological patients.
R. Rodnitzky (1982)
Clinical pharmacology of systemic steroids
JC Melby (1977)
10.1038/85520
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
W. Hoch (2001)
10.1002/(SICI)1097-4598(199608)19:8<959::AID-MUS4>3.0.CO;2-7
Acute effects of intravenous injection of beta‐adrenoreceptor‐ and calcium‐channel antagonists and agonists in myasthenia gravis
Iris Jonkers (1996)
Serologic profile of myasthenia gravis and distinction from the Lambert – Eaton syndrome
VA Lennon (1997)
10.1002/ana.10400
Treatment of refractory myasthenia: “Rebooting” with high‐dose cyclophosphamide
D. Drachman (2003)
Theophylline compounds and myasthenia gravis
J Brumlik (1973)
10.1159/000116916
Myasthenia gravis and invasive thymoma. A 20-year experience.
N. Wakata (1993)
On the treatment of myasthenia gravis.
A. Szobor (1969)
10.1177/028418517801900207
Malignant Thymoma with Renal Metastases
S. Hietala (1978)
The human thymus in disease with particular emphasis on thymitis and thymoma. In: Kendall MG, editor. The thymus gland
K. Henry (1981)
10.1212/WNL.39.10.1359
Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end‐plate in minimal myasthenia gravis
M. Tsujihata (1989)
10.1159/000185605
Abnormal metabolism of type-IV collagen in normotensive non-insulin-dependent diabetes mellitus patients.
Y. Sumida (1997)
10.1055/S-2003-41135
Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
J. Newsom‐Davis (2003)
10.1159/000064491
Evaluation of High-Dose Estrogen and High-Dose Estrogen plus Methyltestosterone Treatment on Cognitive Task Performance in Postmenopausal Women
A. Wisniewski (2002)
Fatigue syndromes: a comparison of chronic “postviral” fatigue with neuromuscular and affec504 Myasthenia Gravis MUSCLE & NERVE April 2004 tive disorders
S Wessely (1989)
10.1212/WNL.39.9.1150
Ocular pseudomyasthenia or ocular myasthenia 'plus': a warning to clinicians.
G. Moorthy (1989)
10.1212/WNL.42.3.516
The frequency of selective IgA deficiency in myasthenia gravis
R. Liblau (1992)
10.1016/0002-9343(83)91122-1
Recurrence of thymic hyperplasia after thymectomy in myasthenia gravis. Its importance as a cause of failure of surgical treatment.
M. Rosenberg (1983)
10.1055/S-2003-40755
The edrophonium test.
R. Pascuzzi (2003)
10.1212/WNL.47.3.840
Assessment of plasmapheresis
Lippincott Williams Wilkins (1996)
Report . Assessment of plasmapheresis
CD Thomas (1996)
10.1016/S0003-4975(03)00488-0
Thymectomy for myasthenia gravis: evaluation requires controlled prospective studies.
A. Jaretzki (2003)
Striated muscle antibody and computed tomography may miss invasive thymoma in myasthenia gravis
J C Keesey (1986)
10.1007/978-1-59259-341-5_6
Thymoma-Associated Myasthenia Gravis
A. Marx (2003)
10.1097/00005792-197809000-00002
MYASTHENIA GRAVIS IN PATIENTS WITH THYMOMA, WITH PARTICULAR REFERENCE TO ONSET AFTER THYMECTOMY
N. Brunner (1978)
Contemporary opinions about Mary Walker , a shy pioneer of therapeutic
JC Keesey (1998)
10.1212/WNL.40.5.786
The relationship of age to outcome in myasthenia gravis
D. Donaldson (1990)
10.1212/WNL.51.4.1198
The long-term clinical outcome of myasthenia gravis in patients with thymoma
V. Bril (1998)
10.1001/ARCHNEUR.1972.00490100080008
Blood flow in extraocular muscle of cat.
G. Wooten (1972)
Myasthenia gravis in infancy. Neurology 1981;31:476–480
ME Seybold (1981)
10.1212/WNL.48.Suppl_5.40S
Seronegative myasthenia gravis
D. Sanders (1997)
10.1212/WNL.40.4.581
Immune studies in human immunodeficiency virus infection with myasthenia gravis
A. Nath (1990)
10.7326/0003-4819-109-7-554
The frequency of the chronic fatigue syndrome in patients with symptoms of persistent fatigue.
P. Manu (1988)
10.1055/S-2008-1041258
Adverse drug effects on neuromuscular transmission.
J. Howard (1990)
10.1196/annals.1254.053
The Epidemiology of Myasthenia Gravis
L. H. Phillips (1994)
10.1212/WNL.56.1.94
Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
V. Chaudhry (2001)
10.1001/ARCHNEUR.1993.00540080046012
Myasthenic Crisis: Response to Plasmapheresis Following Failure of Intravenous γ-Globulin
R. Stricker (1993)
10.1212/WNL.41.4.520
Diagnosis of thymoma in myasthenics using anti-striated muscle antibodies: predictive value and gain in diagnostic certainty.
D. Lanska (1991)
10.1159/000153456
Birth weight and natural selection.
J. Rajanikumari (1984)
10.1016/S0022-510X(98)00031-8
Exacerbation of myasthenia gravis during the menstrual period
R. Leker (1998)
10.1007/978-1-59259-341-5
Myasthenia Gravis and Related Disorders
Henry J. Kaminski (2003)
Chronic limb girdle myasthenia gravis.
A. Vasanth (1993)
Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians
HC Chiu (1987)
Acute bilateral ophthalmoplegia: 60 cases
Keane (1986)
10.1212/WNL.41.6.919
Factors influencing outcome of prednisone dose reduction in myasthenia gravis
M. Miano (1991)
10.1002/1531-8249(200011)48:5<820::AID-ANA24>3.0.CO;2-Q
Myasthenia gravis and myasthenic disorders
D. Sanders (2000)
Contemporary opinions about Mary Walker, a shy pioneer of therapeutic neurology
JC Keesey (1998)
10.1136/jnnp.52.8.940
Fatigue syndromes: a comparison of chronic "postviral" fatigue with neuromuscular and affective disorders.
S. Wessely (1989)
10.1016/S0022-510X(99)00205-1
Does myasthenia gravis affect the brain?
J. Keesey (1999)
Myasthenia gravis. Current concepts.
L. Gutmann (1976)
10.1016/S1474-4422(03)00306-5
Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets
A. Vincent (2003)
10.1056/NEJM197401102900204
Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.
M. Seybold (1974)
10.1002/mus.10141
Clinical impact of single‐fiber electromyography
D. Sanders (2002)
10.1212/WNL.52.3.447
Course and treatment of myasthenia gravis during pregnancy
A. Batocchi (1999)
10.1002/ANA.410430411
Quinidine sulfate therapy for the slow‐channel congenital myasthenic syndrome
C. Harper (1998)
Myasthenia crisis: clinical features, mortality, complications, and risk factors for prolonged intubation
CD Thomas (1997)



This paper is referenced by
10.1097/MD.0000000000023679
Therapeutic efficacy and immunoregulatory effect of Qiangji Jianli Capsule for patients with myasthenia gravis
Senhui Weng (2020)
10.1007/s10072-019-03746-1
Italian recommendations for the diagnosis and treatment of myasthenia gravis
A. Evoli (2019)
10.1016/j.clinph.2013.04.344
Jitter analysis with concentric needle electrode in the masseter muscle for the diagnosis of generalised myasthenia gravis
Elif Kocasoy Orhan (2013)
10.1016/j.prrv.2009.10.009
Overview of paediatric neuromuscular disorders and related pulmonary issues: diagnostic and therapeutic considerations.
M. Yang (2010)
10.1002/mus.20651
Stimulated jitter in the masseter muscle: Normative values
R. Rousseff (2007)
10.1002/mus.20908
Surrogate therapeutic outcome measures in patients with myasthenia gravis
L. Zinman (2008)
10.1007/s13760-016-0689-z
A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients
Athena Alipour-faz (2016)
10.1016/j.ienj.2011.07.001
Myasthenia gravis: a real emergency.
Jared M. Kutzin (2012)
10.1007/978-1-84800-993-6_12
Diseases of the Peripheral Nervous System
C. Hahn (2009)
10.5582/irdr.2019.01121
Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature.
N. Garzón-Orjuela (2019)
10.1038/ncpneuro0033
Autoimmune channelopathies
C. Buckley (2005)
10.1002/mus.21493
Muscle strength and fatigue in patients with generalized myasthenia gravis
C. Symonette (2010)
10.1016/S0121-8123(10)70078-5
Artritis reumatoide y miastenia gravis: reporte de un caso refractario al tratamiento manejado exitosamente con rituximab
D. F. Ávila (2010)
10.1097/01.wco.0000180660.57801.3f
Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis
A. Vincent (2005)
10.3389/fncel.2014.00405
Neuronal involvement in muscular atrophy
Bruno A. Cisterna (2014)
10.1093/labmed/lmy038
A Simple, Rapid and Non-Radiolabeled Immune Assay to Detect Anti-AChR Antibodies in Myasthenia Gravis.
Suresh C. Bokoliya (2018)
10.1111/j.1399-6576.2011.02564.x
A standardized protocol for the perioperative management of myasthenia gravis patients. Experience with 110 patients
P. Gritti (2012)
10.1002/mus.26114
Burden of illness in patients with treatment refractory myasthenia gravis
N. Engel-Nitz (2018)
10.1002/mus.24054
Effects of balance strategy training in myasthenia gravis: A case study series
S. Wong (2014)
10.3109/08916934.2015.1030614
Complicating autoimmune diseases in myasthenia gravis: a review
A. Nacu (2015)
10.1002/14651858.CD010028
Ephedrine for myasthenia gravis
C. Vrinten (2012)
10.5772/32146
Myasthenia Gravis with Anti-MuSK Antibodies: Clinical Features and Histopathological Changes
C. Angelini (2012)
Myasthenia gravis a lé čba pomocí inhibitor ů acetylcholinesterázy
Daniela Brandová (2012)
10.4103/am.am_6_17
Bulbar myasthenia after 7 years of thymectomy
Ramesh Mutiki (2017)
10.1002/mus.20854
Frequency of seronegativity in adult‐acquired generalized myasthenia gravis
K. Chan (2007)
10.1016/j.jns.2007.04.045
Myasthenic crisis: Guidelines for prevention and treatment
A. Jani-Acsadi (2007)
10.1007/s10875-007-9147-2
Thymopoiesis, Regulatory T Cells, and TCRVβ Expression in Thymoma With and Without Myasthenia Gravis, and Modulatory Effects of Steroid Therapy
A. Fattorossi (2007)
10.21037/MED.2018.01.03
Paraneoplastic neurological syndromes associated with mediastinal tumors
R. Iorio (2018)
10.1002/mus.22212
Cost analysis of myasthenia gravis from a large U.S. insurance database
J. Guptill (2011)
10.1016/S0246-0289(10)43358-7
Anesthésie et myasthénie
S. Lammens (2010)
10.1196/annals.1405.012
Response to Therapy in Myasthenia Gravis with Anti‐MuSK Antibodies
A. Evoli (2008)
10.1212/WNL.0b013e3181a41211
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals
A. Alshekhlee (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar